Navigation Links
William Garland Joins AngioGenex's New Board of Directors
Date:1/7/2008

NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- AngioGenex, Inc. (OTC Bulletin Board: AGGX), a New York-based biotechnology company, and the leader in Id targeted anti-angiogenic drug development, announced that its shareholders elected William Garland to the company's Board of Directors at its Annual Meeting. The company also announced that the newly elected Board met and chose founding Director Richard Salvador as its Chairman. As he assumes this new post, Dr. Salvador will continue to serve as acting President and Chief Executive Officer.

"Dr. Garland's knowledge of medicinal chemistry and drug development, as well as his experience with numerous successful early stage biotech companies makes him ideally suited to help guide the company during these pivotal times," said Michael Strage, Vice President for Business Development, who is stepping down as Chairman but will remain on the board. The incoming Chairman added: "After a very productive career at Hoffmann La Roche, Inc., Dr. Garland left to run research and development for a number of successful smaller companies such as Centaur Pharmaceuticals, Atairgin Technologies, Lpath, Inc., Tosk, and AngioGenex. During that time he has managed the successful development of many drugs from pre-clinical studies, through all phases of clinical testing, to regulatory approval. The Board will benefit greatly from his contributions." Following his election, Bill remarked, "The AngioGenex technology remains one of only a handful of truly innovative therapeutic approaches to cancer with breakthrough potential, and I look forward to working with Dick, Michael and the other Board members to accelerate transfer of this technology from the laboratory to the bedside."

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer drugs that prevent the formation of new blood vessels into tumors (angiogenesis) by inhibiting the action of either the Id genes or proteins. The company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. His research established that the Id genes and proteins are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications. The company's research also shows promise for the treatment of ocular diseases such as diabetic retinopathy and age related macular degeneration.

Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are only limited and unsatisfactory therapies. As a result, anti-angiogenesis therapy has been hailed in medical circles as the first new and promising approach for cancer treatment in many years. "The Id mechanism has been demonstrated in the highest levels of the academic community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread," according to Vice-President Michael Strage. "AngioGenex is in a unique proprietary position to exploit these findings as we build a business around the development of pharmaceutical products that can control tumorigenesis and metastasis through Id-inhibition."

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

WEBSITE: AngioGenex.com


'/>"/>
SOURCE AngioGenex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
2. Mediatech Moves to Prince William County Innovation Park
3. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
4. Robin C. Stracey Joins Cantimer, Inc. as President and CEO
5. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
6. Jim Dorst Joins SpectraScience as CFO
7. Chambers Joins PRA International as Senior Vice President of Human Resources
8. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
9. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
10. SAFC Hitech(TM) Joins Aviza and ST Microelectronics for Solid State Technology ALD Webcast
11. Expert Cardiologist Joins Quintiles Medical Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):